ONCR || Genitourinary

I-125 brachytherapy for prostate cancer linked to small increase in bladder cancer risk

Posted on: 25/03/2014 - 14:45

Second primary malignancies affected 10.8% of men who received I-125 brachytherapy as monotherapy for prostate cancer, researchers reported in the April issue of Clinical Oncology. But only bladder...

Field of Interest: Oncology

Type: News Item

No benefit from androgen deprivation therapy in localized prostate cancer

Posted on: 25/03/2014 - 14:00

For most men with localized prostate cancer who defer surgery or radiation, primary androgen deprivation therapy offers no mortality benefit, Dr. Arnold L. Potosky reported. Dr. Potosky of...

Field of Interest: Oncology

Type: News Item

Prostate cancer death rate highest in Montana

Posted on: 13/02/2014 - 15:20

Montana is expected to have the highest rate of prostate cancer deaths in the United States for 2014, and it will be more than twice as high as that of Texas, which should have the lowest rate, the...

Field of Interest: Oncology

Type: News Item

Beta-blockers linked to lower mortality in high-risk prostate cancer

Posted on: 10/02/2014 - 22:25

The use of beta-blockers in men with metastatic and high-risk prostate cancer was associated with a reduced risk of prostate cancer–specific mortality independent of statin or acetylsalicylic acid...

Field of Interest: Oncology

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

I-125 brachytherapy for prostate cancer linked to small increase in bladder cancer risk

No benefit from androgen deprivation therapy in localized prostate cancer

Prostate cancer death rate highest in Montana

Beta-blockers linked to lower mortality in high-risk prostate cancer

Newsletters

Latest Newsletters